Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00534794 · ClinicalTrials.gov registry record · Phase 4
Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis
A Phase 4 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 4
- Development phase
- 79
- Enrollment target
NCT00534794 is a Phase 4 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 79 participants.
The verdict
NCT00534794, a Phase 4 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 79 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis.
Interventions
- DRUG Elestat
- DRUG Pataday
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2007-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00534794
The ClinicalTrials.gov registry entry for NCT00534794 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Elestat is the first listed.
NCT00534794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00534794 about?
NCT00534794 is a clinical study titled "Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis". The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis.
What is the current status of trial NCT00534794?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 79 participants. The study started on 2007-10.
What interventions are being tested in trial NCT00534794?
The interventions under investigation include: Elestat (DRUG), Pataday (DRUG).
Who is sponsoring clinical trial NCT00534794?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.